Jobs
View more job listings or post a job
Aimmune Therapeutics Quality Technical Reviewer, Analytical Development & Quality Control – (Contractor)
Aimmune Therapeutics Project Coordinator, Analytical Development & Quality Control – (Contractor)
Gilead Sciences, Inc. Research Scientist II - Drug Metabolism  
Gilead Sciences, Inc. Associate Scientist II - Drug Metabolism
Gilead Sciences, Inc. Research Scientist I - Nonclinical Safety & Pathobiology  
Gilead Sciences, Inc. Senior Research Associate I, Pathobiology
Gilead Sciences, Inc. Associate Scientist II - Nonclinical Study Monitor, Nonclinical Safety & Pathiobiology  
Charles River Laboratories Senior Sales Specialist
Charles River Laboratories Senior Sales Specialist
Charles River Laboratories Research Associate
Post a job

Minisymposium

SOT-PBSS Joint Spring Symposium: Immuno-oncology: Opportunities, Therapeutic Approaches, and Safety Considerations


Speakers: Keith Bahjat (Bristol-Myers Squibb), Haleh Saber (FDA), Sunjay Sethi (University of California Davis), Henry QX Li (Crown Bioscience), Greg Bannish (Envigo), Rodney Prell (Genentech), Herve Lebrec (Amgen Inc.), Allyson Byrd (Genentech)
Organizers:
Date: 4/27/2018
Time: 8:00-17:00
Registration fee (USD): Regular: $50;
Location: South San Francisco Conference Center (255 South Airport Boulevard, South San Francisco, CA 94080)
Major Sponsor:
Vendor show vendors registered to date: (1)PHARMout Laboratories
Registration: http://www.PBSS.org
Registration deadline:4/22/2018  (it will close sooner if the seating cap is reached)

About the Topic

Over the past decade, tremendous progress has been made in understanding the interplay between the immune system and cancer. Consequently, cancer immunotherapy (aka immuno-oncology), which is intended to induce or enhance an immune response to the cancer, has had several recent approvals and seen remarkable growth in discovering and developing new and exciting technologies. Many research institutions and pharmaceutical companies have promising research programs which involve novel drug targets on immune cells, or which utilize therapeutic approaches designed to engage the immune system to kill the cancer cells.

This year’s joint symposium between NorCal SOT and PBSS will involve presentations describing the interplay between the immune system and cancer and therapeutic approaches which harness the power of the immune system as a means to treat cancer. There will also be in-depth presentations on safety assessment for new immuno-oncology drugs, including presentations by pharmaceutical safety assessment scientists on several of the leading therapeutic approaches- checkpoint inhibitors, T-cell redirecting therapies and adaptive cell transfer/CAR-T cells, as well as perspectives from an FDA reviewer on the unique challenges with developing cancer immunotherapeutics. In addition, there will be presentations summarizing animal models to support preclinical research, clinical challenges in developing immune therapies and how the microbiome can influence the immune system and thus cancer immunotherapies.

 

Agenda 

Morning Session 

7:30 am – 8:30 am            Registration & Breakfast

8:30 am – 8:45 am            Opening Messages from the NorCal SOT & PBSS Presidents

  • Doris Zane, PhD, DABT, Senior Director, Preclinical Development, Intarcia Therapeutics, Inc.
  • Shichang Miao,PhD, Vice President, Preclinical Development and Clinical DMPK, ChemoCentryx Inc.

8:45 am – 9:25 am            Presentation 1: A Brief History of Immunotherapy,

  • Keith Bahjat, PhD, Director, Bristol-Myers Squibb

9:25 am – 10:10 am          Presentation 2: Immune-Oncology: Nonclinical Challenges

  • Haleh Saber, PhD, Deputy Director, Division of Hematology Oncology Toxicology, FDA

10:10 am – 10:25 am       Coffee Break

10:25 am – 10:50 am       NorCal Student Award presentation: Influence of Genetic Background onPolychlorinated Biphenyl (PCB) Developmental Neurotoxicity

  • Sunjay Sethi, Graduate Student, University of California Davis

10:50 am – 11:30 am       Presentation 3: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model

  • Henry QX Li, PhD, Senior Vice President, Global Scientific Research and Innovation Division, Crown Bioscience 

11:30 am – 12:10 pm       Presentation 4: Title TBD (Topic – Preclinical development – animal models for selecting/optimizing drug candidates)

  • Greg Bannish, PhD, Vice President, Biopharmaceutical Development, Envigo 

12:10 pm – 1:40 pm         Lunch Break: Lunch with Experts, Posters

 

Afternoon Session

1:40 pm – 1:55 pm           Chapter Announcements and Acknowledgements 

1:55 pm – 2:35 pm           Presentation 5: Nonclinical Safety Challenges for Cancer Immunotherapeutics

  • Rodney Prell, PhD, DABT, Principal Scientist/Toxicologist, Genentech 

2:35 pm – 3:15 pm           Presentation 6: Nonclinical Safety Assessment of CARTs: A Multipronged Approach

  • Herve Lebrec, PhD, DABT, Scientific Director, Amgen Inc. 

3:15 pm – 3:30 pm           Coffee Break 

3:30 pm – 4:00 pm           Presentation 7: Microbiome Research as an Innovative Platform for Biomarker and Drug Discovery

  • Allyson Byrd, PhD, Genentech 

4:00 pm – 4:05 pm           Closing Remarks 

4:05 pm – 5:00 pm           Reception & Networking

 


2018-08-03, The New EMA Guideline and Evolving Expectations for Patient Safety in First-in-Human Clinical Trials: Keeping the Focus on the Science
2018-09-12, Antibody Drug Conjugates: Chemistry, Biology, Pharmacokinetics and Toxicology
2018-09-27, Small Molecule Formulation Development: Strategies for challenging APIs (jointly with AAPS-BADG)
2018-10-16, Drug-Drug Interactions: Preclinical Risk Assessment and Review of the new FDA Guidance
2018-11-01, cGMP Compliance for Quality Control and Laboratory Operations
2018-11-16, Protein therapeutics and biomarkers: Recent developments in characterization and quantification by hybrid LC-MS
2018-12-04, Challenges in Peptide Discovery & Drug Development: Biology, Chemistry, PK, Delivery, Regulatory and Beyond
©Pharmaceutical & BioScience Society, International; Last Modified: 7/20/2018; Visited: 224; Admin Logon
Ads (in random order)
Submit a Text Ad
($200 for 2 months)

Pharm-Olam International Pharm-Olam is a midsize CRO offering a wide range of Phase I-IV comprehensive, clinical research services to the pharma, biotech & device industries.
Simulations Plus GastroPlus™ PBPK modeling workshops scheduled around the globe to train scientists on the new guidance documents from the FDA and EMA. Register today!
Simulations Plus GastroPlus™ developers launch PKPlus™. Generate validated PK reports for regulatory submissions. Value pricing/licensing. Request an evaluation today.
Nuventra Pharma Sciences With a background in clinical pharmacology and PK/PD, Nuventra enables our clients to make better strategic decisions.
Charles River 2nd Annual Viral Summit The 2-day summit unites industry experts in an interactive setting to share updates and discuss trends in viral safety and viral clearance.
Pharmaron Our Vision: To become the world-leading small-molecule life science R&D service company, supporting our partners from discovery to commercialization
Solid Form Solutions Ltd Solid Form Solutions Ltd CRO providing Solid State Crystallization and Analytical Testing Services to the pharma/biotech industries.
Simulations Plus The new ADMET Predictor™ 8.5 - Powerful ADMET Property Estimation, at your fingertips! Request an evaluation today.
MicroConstants MicroConstants is a GLP-compliant Contract Research Organization focused on performing regulated bioanalysis, drug metabolism and PK analysis.
INTERTEK PHARMACEUTICAL SERVICES Intertek, a bioanalytical CRO (drugs, biologics, proteins, ADCs, biosimilar, generics, peptide, biomarker, immunogenicity, ADA, Nab) in San Diego CA
Reaction Biology Corporation (RBC) RBC provides kinase & epigenetic assays and proteins for early-stage programs. Contact: kelvin.lam@reactionbiology.com
S-Matrix Fusion QbD® Software – Analytical Method Development & Validation, Formulation & Process R&D. Works with ChemStation, Chromeleon, and Empower.
Hypha Discovery Specialists in provision of drug metabolites at mg-g scale, including CYP/Non-CYP metabolites and conjugates such as glucuronides/sulfates.
Avecia Pharma Services Nitto Avecia Pharma provides GMP contract development and parenteral manufacturing services to the pharma/biotech industries. Visit our Irvine labs!
Protein Characterization Seminar hosted by Charles River Join us in San Diego on September 15, 2017 to discuss the analytical methods used to detect process residuals and determine biosimilarity.
Sirius Analytical Services and Automated Instruments for pKa, log P/D, solubility, dissolution. New Scissor instrument for sub-cutaneous injection site simulation.
Zef Scientific California’s premier multi-vendor LC-MS/MS engineering firm with highest level of services & rapid onsite response on all major brands & models.
Clinverse Inc. A global technology company solely focused on automating the financial management of clinical trials.
Pacific BioLabs Offers toxicology,microbiology,analytical and bioanalytical services with a combination of technical expertise & rigorous quality systems.
Simulations Plus Are you ready to integrate in silico modeling & simulation to augment your research activities, but don’t have the time or resources? We can help!
PHARMA INVENTOR Vancouver based Canadian Custom Synthesis Services Company, Offers Inventive & Cost-Effective Chemical Synthesis Services to Life Sciences Industries.
Nektar Therapeutics Sr. Scientist - Bioanalytical Contributes to the development, validation, and implementation of ligand-binding assays. PhD and 5 years exp.
Submit a Text Ad